Proof-of-concept study to assess impact of glycemic variability

June 25, 2015

Proof-of-concept study to assess impact of glycemic variability
(HealthDay)—A proof-of-concept study will be able to examine the contribution of glycemic variability to outcomes of type 2 diabetes, according to a report published online June 11 in Diabetes Care.

Jeffrey L. Probstfield, M.D., from the University of Washington in Seattle, and colleagues enrolled patients with insulin-requiring type 2 diabetes and high cardiovascular risk during a run-in period on basal bolus insulin (BBI). In an effort to maintain hemoglobin A1c (HbA1c) levels between 6.7 and 7.3 percent, 102 patients were randomly allocated to continue BBI or to with a prandial GLP-1 receptor agonist for six months. The primary outcome was glycemic variability, assessed by continuous glucose monitoring.

The researchers note that the mean age of the population was 62 years at randomization, with median diabetes duration of 16 years. Participants had a mean body mass index of 34 kg/m² and HbA1c of 7.9 percent. Of the patients, 32, 18, and 3 percent had a prior cardiovascular event, microalbuminuria, and macroalbuminuria, respectively. Between the groups, the continuous glucose monitoring coefficient of variation for was similar at baseline.

"We successfully randomized a population that has sufficient power to answer the primary question, address several secondary ones, and complete the protocol as designed," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which is primarily funding the trial. Several have providing study funding and/or in-kind donations for the study.

Explore further: Low serum 25(OH)D3 in patients newly diagnosed with T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Low serum 25(OH)D3 in patients newly diagnosed with T2DM

June 15, 2015
(HealthDay)—Serum 25-hydroxyvitamin D3 (25[OH]D3) is associated with glucose-stimulated insulin secretion and β-cell function in individuals with newly diagnosed type 2 diabetes, according to a study published online June ...

Gender-based differences in glycemic control in T2DM

May 26, 2015
(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...

Insulin LY2605541 tops glargine for glycemic control in T1DM

January 13, 2013
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

Glycemic variability elevates risk of vascular events, death

May 16, 2014
(HealthDay)—Visit-to-visit variability (VVV) in glycated hemoglobin (HbA1c) and fasting glucose correlate with major adverse outcomes for patients with type 2 diabetes, according to a study published online May 8 in Diabetes ...

Intensive insulin rx lowers glycemic variability in early DM

April 15, 2014
(HealthDay)—Short-term intensive insulin therapy (IIT) can improve β-cell function in type 2 diabetes mellitus (T2DM) in association with decreased glycemic variability, according to a study published in the April issue ...

Islet transplantation safe, efficient in five-year follow-up

June 23, 2015
(HealthDay)—Islet transplantation seems safe and efficient for restoring glycemic control in type 1 diabetes, according to research published online June 11 in Diabetes Care.

Recommended for you

A novel insulin accelerant

October 17, 2018
Insulin levels rise after eating a meal, signaling uptake of circulating glucose by skeletal muscle. In individuals with diabetes this process is often impaired—a condition known as insulin resistance.

Fat tissue may play a crucial role in the progression of diabetes, challenging long established notions

October 12, 2018
A new study by Australian researchers, out today, is challenging what we know about the causes of diabetes. The new research points to fat tissue as a source of disease, and widens our understanding beyond the traditional ...

Does breastfeeding hormone protect against type 2 diabetes?

October 12, 2018
(HealthDay)—The hormone prolactin—most commonly associated with breastfeeding—may play a role in reducing the risk of type 2 diabetes, a new study suggests.

Planned intermittent fasting may help reverse type 2 diabetes, suggest doctors

October 10, 2018
Planned intermittent fasting may help to reverse type 2 diabetes, suggest doctors writing in the journal BMJ Case Reports after three patients in their care, who did this, were able to cut out the need for insulin treatment ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

New discovery restores insulin cell function in type 2 diabetes

October 8, 2018
By blocking a protein, VDAC1, in the insulin-producing beta cells, it is possible to restore their normal function in case of type 2 diabetes. In preclinical experiments, the researchers behind a new study have also shown ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.